← Leaderboards
Alexander John Maclennan
University Of Cincinnati
$6,099,984
Attributed
$6,099,984
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $687.1K · FY2006–23$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,099,984 · 5
By mechanism
R01$6,099,984 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Motor Neurons”
- Merit E Cudkowicz · Massachusetts General Hospital$50,666,157
- Jerrold L Vitek · University Of Minnesota$28,920,065
- Daniel M Corcos · Northwestern University$27,398,302
- Richard A Andersen · California Institute Of Technology$25,841,240
- Martyn D Goulding · Salk Institute For Biological Studies$22,530,165
- Peter L Strick · University Of Minnesota Twin Cities$20,725,006
Research focus
Motor NeuronsImmunohistochemistryCiliary Neurotrophic FactorCiliary Neurotrophic Factor ReceptorGeneticReportingIn Situ HybridizationDesignResponseCell TypeEffective TherapyLigandsProductionFutureSiteMotorProteinsLesionCessation Of LifeNerveMuscleAdultIn VivoInjection Of Therapeutic Agent
Grant awards (20)
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS$405,917
R01 · FY2023 · NS · contact PI
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS$405,917
R01 · FY2022 · NS · contact PI
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS$405,917
R01 · FY2021 · NS · contact PI
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS$417,923
R01 · FY2020 · NS · contact PI
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS$424,160
R01 · FY2019 · NS · contact PI
Endogenous CNTF receptors and adult, in vivo neurogenesis$324,117
R01 · FY2013 · NS · contact PI
Endogenous CNTF receptors and adult, in vivo neurogenesis$335,502
R01 · FY2012 · NS · contact PI
Endogenous CNTF receptors and adult, in vivo neurogenesis$335,639
R01 · FY2011 · NS · contact PI
Endogenous CNTF receptors and adult, in vivo neurogenesis$344,432
R01 · FY2010 · NS · contact PI
Endogenous CNTF receptors and adult, in vivo neurogenesis$351,782
R01 · FY2009 · NS · contact PI
CNTF Receptors: Neuromuscular Protection/Repair In Vivo$335,359
R01 · FY2009 · NS · contact PI
CNTF Receptors: Neuromuscular Protection/Repair In Vivo$335,359
R01 · FY2008 · NS · contact PI
CNTF Receptors: Neuromuscular Protection/Repair In Vivo$335,359
R01 · FY2007 · NS · contact PI
CNTF Receptors: Neuromuscular Protection/Repair In Vivo$345,375
R01 · FY2006 · NS · contact PI
CNTF RECEPTORS AND NEUROPROTECTION AFTER BRAIN TRAUMA$224,714
R01 · FY2002 · NS
CNTF RECEPTORS AND NEUROPROTECTION AFTER BRAIN TRAUMA$218,170
R01 · FY2001 · NS
CNTF RECEPTOR ALPHA REGULATION AND FUNCTION$184,516
R01 · FY2001 · NS
CNTF RECEPTORS AND NEUROPROTECTION AFTER BRAIN TRAUMA$200,049
R01 · FY2000 · NS
CNTF RECEPTOR ALPHA REGULATION AND FUNCTION$108,453
R01 · FY2000 · NS
CNTF RECEPTOR ALPHA REGULATION AND FUNCTION$61,324
R01 · FY2000 · NS